Early administration of fibrinolytics after surgical treatment of peritonitis in the rat reduces abscess formation. The current study investigates the effect of various treatment protocols using intraperitoneal recombinant tissue plasminogen activator (rtPA). Peritonitis was induced in rats and surgical debridement was performed after 1 hour. Animals were treated with rtPA at different time points. Abdominal fluid samples were taken at 24, 72, and 120 hours for cytokine measurements and cell counts. After 5 days the abdomen was inspected for abscesses. Early administration of rtPA significantly reduced the number of rats with abscesses and the abscess load per rat. Delayed treatment significantly reduced abscess load but not the incidence of abscesses. No meaningful differences in the local inflammatory response were found. rtPA was most effective when applied early and continued for 72 hours, although mortality increased after prolonged treatment. rtPA consistently reduces intra-abdominal abscess formation, and a clinical study seems warranted.
Lamme B., Boermeester MA, Belt EJ, van Till JW, Gouma DJ, Obertop H.Mortality and morbidity of planned relaparotomy versus relaparotomy on demand for secondary peritonitis. Br J Surg. 2004 ;91:1046-1054.
4.
Schein M.Surgical management of intra-abdominal infection: is there any evidence? Langenbecks Arch Surg. 2002;387: 1-7.
5.
Marshall JC, Innes M.Intensive care unit management of intra-abdominal infection. Crit Care Med. 2003;31: 2228-2237.
Sirinek KRDiagnosis and treatment of intra-abdominal abscesses. Surg Infect (Larchmt). 2000;1:31-38.
8.
Rotstein OD, Kao J.Prevention of intra-abdominal abscesses by fibrinolysis using recombinant tissue plasminogen activator. J Infect Dis. 1988;158:766-772.
9.
van Goor H., de Graaf JS, Kooi K., et al. Effect of recombinant tissue plasminogen activator on intra-abdominal abscess formation in rats with generalized peritonitis. J Am Coll Surg. 1994;179:407-411.
10.
Buyne OR, Bleichrodt RP, Verweij PE, Groenewoud HM, van Goor H., Hendriks T.A peritonitis model with low mortality and persisting intra-abdominal abscesses . Int J Exp Pathol. 2006;87:361-368.
11.
Buyne OR, Bleichrodt RP, van Goor H., Verweij PE, Hendriks T.Tissue-type plasminogen activator prevents formation of intra-abdominal abscesses after surgical treatment of secondary peritonitis in a rat model. Int J Colorectal Dis. 2007;22:819-825.
12.
Buyne OR, van GH, Bleichrodt RP, Verweij PE, Hendriks T.Both tissue-type plasminogen activator and urokinase prevent intraabdominal abscess formation after surgical treatment of peritonitis in the rat. Surgery. 2008;144:66-73.
13.
Hartl WH, Wolf H., Schneider CP, Kuchenhoff H., Jauch KWSecular trends in mortality associated with new therapeutic strategies in surgical critical illness. Am J Surg. 2007 ;194:535-541.
14.
van Goor H. , de Graaf JS, Kooi K., Bleichrodt RPGentamycin reduces bacteremia and mortality rates associated with the treatment of experimental peritonitis with recombinant tissue plasminogen activator. J Am Coll Surg. 1995;181:38-42.
15.
Buyne OR, Bleichrodt RP, van GH, Verweij PE, Hendriks T.Plasminogen activator, but not systemic antibiotic therapy, prevents abscess formation in an experimental model of secondary peritonitis. Br J Surg. 2008;95:1287-1293.
16.
Buyne OR, Bleichrodt RP, de Man BM, et al. Tissue-type plasminogen activator prevents abscess formation but does not affect healing of bowel anastomoses and laparotomy wounds in rats with secondary peritonitis. Surgery. 2009; 146:939-946.
17.
Hau T., Nishikawa RA, Phuangsab A.The effect of bacterial trapping by fibrin on the efficacy of systemic antibiotics in experimental peritonitis. Surg Gynecol Obstet. 1983; 157:252-256.
18.
van Goor H. In vitro studies on the effect of recombinant tissue plasminogen activator on the rat fibrinolytic system. In: Fibrinolytic Therapy in Generalized Peritonitis to Prevent Intra-abdominal Abscess Formation [dissertation]. Nijmegen, The Netherlands: Radboud University Nijmegen Medical Center; 1996:125-134.
19.
van Goor H. , Bom VJ, van der MJ, et al. Pharmacokinetics of human recombinant tissue-type plasminogen activator, administered intra-abdominally, in a rat peritonitis model. Eur Surg Res. 1996;28:287-294.
20.
Khurrum BM, Hua ZR, Batista O., et al. Percutaneous postoperative intra-abdominal abscess drainage after elective colorectal surgery. Tech Coloproctol. 2002;6:159-164.
Renckens R. , Roelofs JJ, Florquin S., et al. Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice. J Immunol. 2006;177:1189-1196.
23.
Faist E., Schinkel C., Zimmer S.Update on the mechanisms of immune suppression of injury and immune modulation . World J Surg. 1996;20:454-459.
24.
Damazo AS, Yona S., Flower RJ, Perretti M., Oliani SMSpatial and temporal profiles for anti-inflammatory gene expression in leukocytes during a resolving model of peritonitis. J Immunol. 2006;176:4410-4418.
25.
Blot S., De Waele JJCritical issues in the clinical management of complicated intra-abdominal infections. Drugs. 2005;65:1611-1620.
26.
Rau B., Kruger CM, Schilling MKProcalcitonin: improved biochemical severity stratification and postoperative monitoring in severe abdominal inflammation and sepsis. Langenbecks Arch Surg. 2004;389:134-144.
27.
Sutton CD, Marshall LJ, Williams N., Berry DP, Thomas WM, Kelly MJColo-rectal anastomotic leakage often masquerades as a cardiac complication . Colorectal Dis. 2004; 6:21-22.
28.
Bell WRPresent-day thrombolytic therapy: therapeutic agents-pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med. 2002 ;3(suppl 2):S34-S44.
29.
Deitcher SR , Jaff MRPharmacologic and clinical characteristics of thrombolytic agents. Rev Cardiovasc Med. 2002; 3(suppl 2):S25-S33.
